Glimepiride is a third generation sulfonylurea compound, which increases the release of insulin from pancreatic beta cells. In addition, Glimepiride increases the activity of intracellular insulin receptors. Studies conducted on adipocytes and skeletal muscle suggest that Glimepiride induces the PI3 kinase (PI3K) and Akt pathway, along with insulin receptor substrate-1/2 and endothelial nitric oxide synthase. Glimepiride also increases osteoblast proliferation and differentiation, which is thought to be related to its ability to activate the PI3K and Akt pathway. Furthermore, Glimepiride enhances intrinsic peroxisome proliferator-activated receptor γ activity. Glimepiride also increases protein expression of glucose transports 1 and 4, and is a potent KIR channel blocker.
1. Inukai, K., et al. 2005. Biochem. Biophys. Res. Commun. 328: 484-490. PMID: 15694373 2. Ma, P., et al. 2010. Metab. Clin. Exp. 59: 359-366. PMID: 19800638
Soluble in DMSO (>10 mg/ml), water (<1 mg/ml at 25° C), and ethanol (<1 mg/ml at 25° C).
Store at room temperature
750.37° C (Predicted)
1.30 g/cm3 (Predicted)
pKa: 5.1 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Rated 5 out of
Ma et alMa et al. (PubMed ID 19800638) found that Glimepiride induced rat osteoblast proliferation and differentiation via PI3-kinase/Akt pathway activation. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn